Document is current
Any future updates will be listed below
-
Authors
Caron, Nicholas S. https://orcid.org/0000-0002-3877-455X
Byrne, Lauren M.
Lemarié, Fanny L.
Bone, Jeffrey N.
Aly, Amirah E.-E.
Ko, Seunghyun
Anderson, Christine
Casal, Lorenzo L.
Hill, Austin M.
Hawellek, David J.
McColgan, Peter
Wild, Edward J.
Leavitt, Blair R.
Hayden, Michael R. https://orcid.org/0000-0001-5159-1419
-
Funding
Funding for this research was provided by:
Huntington's Disease Society of America
Bev Hartig Huntington's Disease Foundation
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 11 September 2024
First Online: 8 October 2024
Declarations
:
: All experiments involving animals were performed with approval from the Animal Care Committee at the University of British Columbia (A16-030 and A20-0107).
: Not applicable.
: DJH and PM are paid employees of F. Hoffmann-La Roche. EJW reports grants from CHDI Foundation and European Huntington’s Disease Network. EJW reports consultancy / advisory board memberships with Alnylam, Annexon, Remix Therapeutics, F. Hoffman-La Roche Ltd, Ionis Pharmaceuticals, PTC Therapeutics, Skyhawk Therapeutics, Takeda, Teitur Trophics, Triplet Therapeutics, Uniqure, Wave Life Sciences, and Vico Therapeutics. He is an investigator on the AMT-130 program. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. BRL is a founder and CEO of Incisive Genetics Inc. MRH is the CEO of Prilenia Therapeutics and serves on the public boards of Ionis Pharmaceuticals, Oxford Biomedica, AbCellera and 89bio.
